155.67 0.00 (0.00%)
After hours: 4:53PM EDT
Previous Close | 158.69 |
Open | 160.27 |
Bid | 145.00 x 100 |
Ask | 162.00 x 1000 |
Day's Range | 154.69 - 160.49 |
52 Week Range | 113.66 - 178.15 |
Volume | 1,223,744 |
Avg. Volume | 1,737,453 |
Market Cap | 39.677B |
Beta | 1.94 |
PE Ratio (TTM) | 149.83 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vertex Pharmaceuticals Incorporated will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m.
Vertex Pharmaceuticals Incorporated today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018, and will report to Michael J.
Vertex Pharmaceuticals Incorporated today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET.
NEW YORK, March 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Vertex Pharmaceuticals Incorporated today announced that it is initiating a Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis who have two copies of the F508del mutation, the most common genetic form of the disease.
Vertex Pharmaceuticals Incorporated today announced that Reshma Kewalramani, M.D., has been appointed Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs, effective April 1, 2018.
Vertex Pharmaceuticals Incorporated today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis who have one F508del mutation and one minimal function mutation.
Vertex Pharmaceuticals Incorporated today announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery.
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration approved SYMDEKO™ for treating the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or who have at least one mutation that is responsive to tezacaftor/ivacaftor.
Stock Monitor: Vertex Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 02, 2018 / Active-Investors.com has just released a free research report on BeiGene, Ltd (NASDAQ: BGNE ). If you ...
Vertex Pharmaceuticals Incorporated today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis .
Vertex Pharmaceuticals Incorporated today reported consolidated financial results for the full year and fourth quarter ended December 31, 2017.
Vertex Pharmaceuticals Incorporated today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis .
NEW YORK, NY / ACCESSWIRE / January 31, 2018 / Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) will be discussing their earnings results in their Q4 Earnings Call to be held on January 31, 2018 at ...
Vertex Pharmaceuticals Incorporated today announced that the European Commission has granted extension of the Marketing Authorization for ORKAMBI® , the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation, to include children ages 6 through 11.
Vertex Pharmaceuticals Incorporated today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:30 p.m. ET (9:30 a.m.
NEW YORK, NY / ACCESSWIRE / December 14, 2017 / Teva shares sank almost 5% yesterday after traders showed concern over calls for protest in Israel over the company planning on cutting thousands of jobs ...
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously announced collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology.
Vertex Pharmaceuticals Incorporated today announced positive results from an open-label Phase 3 study of KALYDECO® in children with cystic fibrosis ages 1 to 2 years who have one of 10 mutations in the cystic fibrosis transmembrane conductance regulator gene.
Research Desk Line-up: Esperion Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Vertex Pharmaceuticals ...
Vertex Pharmaceuticals Incorporated today announced that the European Union Committee for Medicinal Products for Human Use issued a positive opinion recommending extension of the Marketing Authorization for ORKAMBI® to children with cystic fibrosis ages 6 through 11 who have two copies of the F508del mutation.
Vertex Pharmaceuticals Incorporated today announced presentations of data at the Annual North American Cystic Fibrosis Conference , November 2 to 4, 2017, in Indianapolis, from across the company’s portfolio of cystic fibrosis medicines and medicines in development that demonstrate important progress toward the company’s goal of helping all people with CF.
Vertex Pharmaceuticals Incorporated announced today that the New England Journal of Medicine published two articles with results from two Phase 3 studies of the tezacaftor/ivacaftor combination treatment, a medicine in development that is designed to treat the underlying cause of cystic fibrosis in people ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance ...
Vertex Pharmaceuticals Incorporated today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.m.